anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

216,001-216,060 of 319,975

filter-aware
07
Includes a scatter plot of vintage vs market multiple and a waterfall-style bridge for proceeds.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations Beat · Solution (Provide relief)Loop · Before After1 hit
08
The slide uses a comparison table to justify a portfolio disposal strategy by showing improved quality metrics in the remaining assets.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations Beat · Solution (Provide relief)Loop · Before After1 hit
09
Hipgnosis Songs Fund | Results Presentation Deck | 22 slidesHipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations Beat · Solution (Provide relief)Loop · Before After1 hit
10
The slide outlines the strategic rationale and operational details of a 'Go-Shop' provision in a transaction.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
11
Uses a stacked bar chart to visualize the 'out of the money' status of contingent bonus obligations relative to growth rates.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
12
The chart illustrates the bridge from Gross Proceeds to Realised transaction proceeds, compared against the Fair Value.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
13
Hipgnosis Songs Fund | Results Presentation Deck | 22 slidesHipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
14
The slide highlights a shift in fee structure, specifically introducing lower tiers for higher market capitalization levels.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
15
Slide 14 of the deck.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations Beat · DesireLoop · Golden Circle1 hit
16
Includes a specific callout to Goldman Sachs forecasts as the source for growth data.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations Beat · DesireLoop · Golden Circle1 hit
17
Hipgnosis Songs Fund | Results Presentation Deck | 22 slidesHipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations Beat · Interest1 hit
18
Hipgnosis Songs Fund | Results Presentation Deck | 22 slidesHipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations Beat · Interest1 hit
19
Hipgnosis Songs Fund | Results Presentation Deck | 22 slidesHipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
20
The slide compares 'Pre First Disposal' vs 'Post First Disposal' metrics for Borrowing Policy and RCF LTV Covenant.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
21
The chart shows a positive correlation between two variables (likely catalogue size/revenue and valuation multiple).Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
22
Features the company logo.Hipgnosis Songs Fund | Results Presentation Deck | 22 slides · Hipgnosis Songs Fund
Activist deck Investor relations 1 hit
01
Slide 1
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
02
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
03
This is a classic 'problem-solution' framing slide.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Solution1 hit
05
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Solution1 hit
06
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Loop · Golden Circle1 hit
07
The table uses a traffic light system (green, yellow, red) to visually indicate performance across categories.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Market Size1 hit
08
The slide uses a comparison framework to contrast traditional vs. new product workflows.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Market Size1 hit
09
The slide uses a before-after framing to contrast traditional centralized MRI with the decentralized Swoop system.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
10
Uses a process flow diagram to illustrate the evolution from current commercial use to future expansion.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
11
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
12
The slide uses a list of specific study examples to build credibility.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
13
The slide highlights regulatory milestones as a proxy for product validation and market readiness.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
14
The central icon represents the Hyperfine device, surrounded by five support pillars.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses a diagonal timeline layout to represent product evolution.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
16
The 2023 figure is marked with an asterisk indicating revenue guidance.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
17
The chart shows a progression from negative margin to positive margin.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a bar chart to demonstrate financial discipline and outlines three key areas of investment.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
19
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Team1 hit
20
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
21
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
22
The slide serves as a bibliography of peer-reviewed research supporting the company's portable MRI technology.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
01
Slide 1
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
02
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
03
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
04
The slide uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative outcomes.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
05
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
06
The slide uses a visual comparison to highlight the safety advantage of NXC-201, specifically focusing on neurotoxicity and CRS duration.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
07
Uses a visual icon-grid to represent market expansion from 5% of hospitals to a much broader network.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
08
The slide uses a molecular biology diagram to illustrate the structural difference in the binding domain of the NXC-201 therapy compared to competitors.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
09
Includes comparative bar charts and flow cytometry data.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Aha Moment1 hit
10
The slide uses a comparative timeline/chart layout to contrast clinical outcomes of three different therapies.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Aha Moment1 hit
11
The chart demonstrates the efficacy of NXC-201 (formerly HBI0101) in clearing diseased cells.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
12
The slide uses a process flow diagram to connect cellular pathology to clinical symptoms in the heart, liver, and kidneys.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
13
Includes extensive source citations in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
14
The slide uses a table structure to contrast treatment outcomes and patient growth across three stages of multiple myeloma.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
16
Includes FDA approval precedents in the footer to establish credibility.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
17
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
18
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
19
The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
20
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and highlighting specific regulatory and clinical trial milestones.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
21
Combines market sizing data with a 'Why Now' narrative supported by industry news clippings and a comparative efficacy table.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit
22
The slide uses a wave-like visual to represent market segments and their associated valuations.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit